Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two cheap blood ratios put to the test as sepsis death predictors

NCT ID NCT07819708

Knowledge-focused Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Sepsis and septic shock cause organ failure and death, and doctors need simple ways to flag the patients most at risk. Researchers at Benha University Hospital followed 60 adults with sepsis or septic shock in a surgical intensive care unit for 28 days. They compared two ratios calculated from routine blood tests, neutrophil-to-lymphocyte and lactate-to-albumin, to see which one better predicts who dies within 28 days. The study also tracked intensive care unit stay length and changes in organ dysfunction scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If one ratio predicts death risk better, doctors could use a routine blood test to spot the sickest sepsis patients sooner and direct intensive care to them.
What could go wrong
This is a small observational study of 60 people at one hospital, so it cannot prove either ratio causes or prevents death, and the results may not hold in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Oct 2025

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 18 to 60 years with clinically confirmed sepsis or septic shock who were admitted to the Surgical Intensive Care Unit at Benha University Hospital and met the predefined study eligibility criteria. Participants underwent clinical and laboratory assessment and were followed for 28 days to evaluate mortality, intensive care unit length of stay, and progression of organ dysfunction.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 60 years with clinically confirmed sepsis or septic shock. * Male and female patients. * Fulfillment of at least two quick Sequential Organ Failure Assessment criteria, including: * Glasgow Coma Scale score less than 15. * Systolic blood pressure less than 100 millimeters of mercury. * Respiratory rate greater than 22 breaths per minute. * Evidence of infection-related organ dysfunction demonstrated by an increase of more than 2 points in the Sequential Organ Failure Assessment score. * Evidence of organ dysfunction, including one or more of the following: * Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen less than 300. * Glasgow Coma Scale score less than 15. * Mean arterial pressure less than 70 millimeters of mercury. * Serum creatinine greater than 1.2 milligrams per deciliter. * Urine output less than 0.5 milliliters per kilogram per hour. * Serum bilirubin greater than 1.2 milligrams per deciliter. * Platelet count less than 150,000 per microliter. * For patients with septic shock, persistent hypotension requiring vasopressors to maintain mean arterial pressure above 65 millimeters of mercury and serum lactate greater than 2 millimoles per liter despite adequate fluid resuscitation. * Ability of the patient or legally authorized representative to provide informed consent. Exclusion Criteria: * Active malignancy or chemotherapy within the previous 3 months. * Corticosteroid therapy within 90 days before admission. * Documented severe liver or kidney dysfunction. * Clinical conditions requiring albumin administration. * Pregnancy or breastfeeding. * Insufficient laboratory data or inability to complete follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Septic shock

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.